EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancertreatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6– (CK5/6–) group, 11.2% of the HER-2–, EGFR+, CK5/6– group, and 19.1% of the HER-2–, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.
Abstract
Background: The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancertreatment. Methods: A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification. Results: EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6– (CK5/6–) group, 11.2% of the HER-2–, EGFR+, CK5/6– group, and 19.1% of the HER-2–, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6. Conclusions: EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.
참고문헌 (28)
- Onitilo AA, "Breast cancer subtypes based on ER", PR and HER2 expression: comparison of clinicopathologic features and survival, 2009, pp.7, 4~13
- Lin C, "Triple negative breast carcinoma is a prognostic factor in Taiwanese women", BMC Cancer, 9, pp.192~ (2009)
- Tsutsui S, "Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer", Clin Cancer Res, 8, pp.3454~3460 (2002)
- Cho EY, "Expression and amplification of HER2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization", Pathol Int, 58, pp.17~25 (2008)
- Tang Y, "Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer", J Transl Med, 10(Suppl 1), pp.S4~ (2012)
- Yu H, "Co-expression of EGFRvIII with ErbB-2 enhances tumorigenesis: EGFRvIII mediated constitutively activated and sustained signaling pathways, whereas EGF-induced a transient effect on EGFR-mediated signaling pathways", Cancer Biol Ther, 7, pp.1818~1828 (2008)
- Hirsch FR, "Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib", Ann Oncol, 18, pp.752~760 (2007)
- Moroni M, "Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study", Lancet Oncol, 6, pp.279~286 (2005)
- Vokes EE, "Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers", Oncology (Williston Park), 20(5 Suppl 2), pp.15~25 (2006)
- Nguyen KS, "First-line treatment of EGFR-mutant non-smallcell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors", Biologics, 6, pp.337~345 (2012)
- Al-Kuraya K, "Prognostic relevance of gene amplifications and coamplifications in breast cancer", Cancer Res, 64, pp.8534~8540 (2004)
- Shao MM, "Epidermal growth factor receptor gene amplification and protein overexpression in basal-like carcinoma of the breast", Histopathology, 59, pp.264~273 (2011)
- Bhargava R, "EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations", Mod Pathol, 18, pp.1027~1033 (2005)
- Masuda H, "Role of epidermal growth factor receptor in breast cancer", Breast Cancer Res Treat, 136, pp.331~345 (2012)
- Nakajima H, "Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer", Breast Cancer (2012)
- Milanezi F, "EGFR", HER2 in breast cancer: a biological approach for molecular diagnosis and therapy, 2008, pp.8, 417~434
- Varella-Garcia M, "EGFR fluorescence in situ hybridisation assay: guidelines for application to non-smallcell lung cancer", J Clin Pathol, 62, pp.970~977 (2009)
- Gumuskaya B, "EGFR expression and gene copy number in triple-negative breast carcinoma", Cancer Genet Cytogenet, 203, pp.222~229 (2010)
- Fulford LG, "Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast", Histopathology, 49, pp.22~34 (2006)
- Livasy CA, "Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma", Mod Pathol, 19, pp.264~271 (2006)
- Piccart-Gebhart MJ, "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer", N Engl J Med, 353, pp.1659~1672 (2005)
- Elkin EB, "HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis", J Clin Oncol, 22, pp.854~863 (2004)
- Park K, "EGFR gene and protein expression in breast cancers", Eur J Surg Oncol, 33, pp.956~960 (2007)
- Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
- Qian X, "Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation", Proc Natl Acad Sci U S A, 91, pp.1500~1504 (1994)
- Jin Q, "Cross-talk between the ErbB", HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer, 2008, pp.13, 485~498
- Zhang D, "Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer", Clin Cancer Res, 15, pp.6639~6648 (2009)
- Carey LA, "The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes", Clin Cancer Res, 13, pp.2329~2334 (2007)